130955-37-2

Usage

Uses

Used in Pharmaceutical Industry:
2,5,8,11-Tetraoxatridecan-13-ol, methanesulfonate is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its mesyl group facilitates nucleophilic substitution reactions, making it a versatile building block for the development of new drugs.
Used in Drug Delivery Systems:
In the field of drug delivery, 2,5,8,11-Tetraoxatridecan-13-ol, methanesulfonate is used as a component in the design of targeted drug delivery systems. The hydrophilic PEG spacer improves the solubility and stability of drug carriers in aqueous environments, enhancing the bioavailability and therapeutic efficacy of encapsulated drugs.
Used in Organic Synthesis:
2,5,8,11-Tetraoxatridecan-13-ol, methanesulfonate is utilized as a reagent in organic synthesis, particularly for the preparation of PEGylated compounds. The presence of the mesyl group allows for efficient nucleophilic substitution, enabling the formation of a wide range of PEGylated products with potential applications in various industries, such as pharmaceuticals, materials science, and biochemistry.

Upstream product

• 23783-42-8 tetraethylene glycol monomethyl ether 
• 124-63-0 methanesulfonyl chloride 
• 128660-97-9 2-(2-(2-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethoxy)ethoxy)ethan-1-ol 
• 727986-31-4 2-(2-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}ethoxy)tetrahydropyran 
• 74654-05-0 8-methoxy-1-(methylsulfonyl)oxy-3,6-dioxaoctane 
• 112-35-6 triethylene glucol monomethyl ether 

Downstream Products

• 130955-40-7 2-(2-{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-1,3-dimethyl-benzene 
• 130955-45-2 C₃₈H₄₆O₉ 
• 720681-03-8 3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid methyl ester 
• 873848-07-8 3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid 
• 873848-25-0 carbonic acid 3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzyl ester 4-nitro-phenyl ester 
• 873848-09-0 3,5-Bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid (2S,3R,4R,5S,6R)-2-allyloxy-5-hydroxy-6-hydroxymethyl-3-(2,2,2-trichloro-ethoxycarbonylamino)-tetrahydro-pyran-4-yl ester 
• 873848-13-6 N-[4-((2S,3R,4S,5R,6R)-4-Benzyloxy-5-hydroxy-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3-yloxymethyl)-phenyl]-3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzamide 
• 873848-08-9 3,5-Bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid (2R,4aR,6S,7R,8R,8aS)-6-allyloxy-2-phenyl-7-(2,2,2-trichloro-ethoxycarbonylamino)-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester 
• 873848-12-5 N-[4-((2R,4aR,6S,7R,8S,8aR)-8-Benzyloxy-6-methoxy-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-yloxymethyl)-phenyl]-3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzamide 
• 873848-22-7 C₅₁H₆₅NO₁₉ 
• 873848-26-1 Carbonic acid (2R,3S,4R,5R,6S)-6-allyloxy-5-allyloxycarbonylamino-4-(4-azido-3-chloro-benzyloxy)-3-hydroxy-tetrahydro-pyran-2-ylmethyl ester 3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzyl ester 
• 873848-21-6 C₅₈H₆₉NO₁₉ 
• 873848-28-3 acetic acid 4,5-diacetoxy-6-acetoxymethyl-2-{6-allyloxy-5-allyloxycarbonylamino-2-[3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzyloxycarbonyloxymethyl]-4-hydroxy-tetrahydro-pyran-3-yloxy}-tetrahydro-pyran-3-yl ester 
• 873848-14-7 C₆₁H₈₅Cl₃N₂O₂₆ 

Relevant academic research and scientific papers

Self-Assembly Can Direct Dynamic Covalent Bond Formation toward Diversity or Specificity

With the advent of reversible covalent chemistry the study of the interplay between covalent bond formation and noncovalent interactions has become increasingly relevant. Here we report that the interplay between reversible disulfide chemistry and self-assembly can give rise either to molecular diversity, i.e., the emergence of a unprecedentedly large range of macrocycles or to molecular specificity, i.e., the autocatalytic emergence of a single species. The two phenomena are the result of two different modes of self-assembly, demonstrating that control over self-assembly pathways can enable control over covalent bond formation.

Polymerizable ionic liquids and polymeric ionic liquids: Facile synthesis of ionic liquids containing ethylene oxide repeating unit: Via methanesulfonate and their electrochemical properties

Polymeric ionic liquids have shown great potential in numerous application fields, and an easy access to polymerizable monomer is the key to the polymerized ionic liquids. The polymerizable monomer is usually synthesized via the quaternization of a corresponding bromide, which is usually prepared from bromination of the corresponding alcohol but with a low yield. In this study, a polymerizable monomer was prepared by quaternization of a mesylate, derived from the corresponding alcohol, followed by an ion exchange reaction. The polymerizable ILs M1-M4 showed ionic conductivity as high as 10-3 S cm-1, and the oxygen effect was observed with the lithium salt. Polymeric ionic liquids P1 and P2 were prepared via radical polymerization on M1 and M2, and the ionic conductivity of polymeric ionic liquid P2 was as high as 2.2 × 10-4 S cm-1 with electrochemical stability exceeding 7 V (vs. Li/Li+).

GLUCOSE UPTAKE INHIBITORS AND USES THEREOF

The present invention relates to novel compounds that modulate cellular glucose uptake by affecting various targets, including, but not limited to those related to glycolysis and known transporters/co-transporters of the GLUT family. The compounds according to the invention are useful for treating cancer such as: neuroendrocrine neoplasms, gastrointestinal stromal tumors (GIST), renal cell carcinoma, paraganglioma, pheochromocytoma, pituitary adenoma, colorectal cancer, lung cancer, gastric cancer, pancreatic cancer sarcoma, head and neck cancer, melanoma, ovarian cancer and other cancers that rely on high levels of glycolysis for survival and proliferation; as well as in treating of autoimmune diseases, inflammation, infectious diseases, and metabolic diseases.

triAZOLOtriAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS

The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.

Site-Selective Modification of Peptides and Proteins via Interception of Free-Radical-Mediated Dechalcogenation

The development of site-selective chemistry targeting the canonical amino acids enables the controlled installation of desired functionalities into native peptides and proteins. Such techniques facilitate the development of polypeptide conjugates to advance therapeutics, diagnostics, and fundamental science. We report a versatile and selective method to functionalize peptides and proteins through free-radical-mediated dechalcogenation. By exploiting phosphine-induced homolysis of the C?Se and C?S bonds of selenocysteine and cysteine, respectively, we demonstrate the site-selective installation of groups appended to a persistent radical trap. The reaction is rapid, operationally simple, and chemoselective. The resulting aminooxy linker is stable under a variety of conditions and selectively cleavable in the presence of a low-oxidation-state transition metal. We have explored the full scope of this reaction using complex peptide systems and a recombinantly expressed protein.

Ionic liquid and preparation method and application of ionic liquid

The invention relates to the field of electrolyte materials and discloses ionic liquid and a preparation method and application of the ionic liquid. The method comprises the following steps: 1) carrying out first reaction on methanesulfonyl chloride and at least one substance with a structure shown as a formula (2); 2) carrying out second reaction on an organic product obtained by the first reaction of the step 1) and a substance with a structure shown as a formula (3). According to the ionic liquid disclosed by the invention, defects that a traditional ionic liquid preparation process is complicated and the safety is low are overcome; the method provided by the invention is simple and feasible; preparation parameters have high controllability; the preparation method has the advantages of low cost and high efficiency; polymerized ionic liquid prepared from the ionic liquid has relatively high ionic conductivity and a wide electrochemical window, and has a very good industrial application prospect. (The formula (2) and the formula (3) are shown as the description.).

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Bna Conjugates and Methods of Use

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, decreasing arterial blood pressure and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, enteral, subcutaneous, pulmonary, and intravenous forms of the compounds and conjugates may be prepared as treatments and/or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the hBNP compound are also disclosed, having an amino acid sequence that is other than the native sequence.

Oligosaccharide synthesis by affinity separation based on molecular recognition between podand ether and ammonium ion

We previously reported a new synthetic methodology termed 'synthesis based on affinity separation' (SAS) in which the desired tagged compound was separated from the reaction mixture by solid-phase extraction using specific molecular recognition of the tag. The interaction between a crown ether tag and polymer-supported ammonium ion was initially employed for SAS. In the present study, a new SAS method using a podand-type tag, a pseudo-benzo-31-crown-10 structure, was elaborated for oligosaccharide synthesis. The podand tag was much easier to synthesize than the corresponding crown ether. The podand moiety was attached to the monosaccharide residue via appropriate linkers. After glycosylation of the tagged monosaccharide with a glycosyl donor, the reaction mixture was subjected to the affinity separation. The desired compounds possessing the podand tag were effectively separated by the affinity between the podand and the ammonium ion. Continuous flow synthesis by integration of a microreactor and the present SAS system was applied for high throughput oligosaccharide synthesis. Georg Thieme Verlag Stuttgart.